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Objective: T-cells are central to the immune response responsible for native atherosclerosis. The objective of
this study is to investigate T-cell contribution to post-interventional accelerated atherosclerosis develop-
ment, as well as the role of the CD28–CD80/86 co-stimulatory and Cytotoxic T-Lymphocyte Antigen
(CTLA)-4 co-inhibitory pathways controlling T-cell activation status in this process.
Methods and results: The role of T-cells and the CD28–CD80/86 co-stimulatory and CTLA-4 co-inhibitory
pathways were investigated in a femoral artery cuff mouse model for post-interventional remodeling, with
notable intravascular CTLA-4+ T-cell inﬁltration. Reduced intimal lesions developed in CD4−/− and
CD80−/−CD86−/− mice compared to normal C57Bl/6J controls. Systemic abatacept-treatment, a soluble
CTLA-4Ig fusion protein that prevents CD28–CD80/86 co-stimulatory T-cell activation, prevented intimal
thickening by 58.5% (p=0.029).
Next, hypercholesterolemic ApoE3*Leiden mice received abatacept-treatment which reduced accelerated
atherosclerosis development by 78.1% (p=0.040) and prevented CD4 T-cell activation, indicated by reduced
splenic fractions of activated KLRG1+, PD1+, CD69+ and CTLA-4+ T-cells. This correlated with reduced
plasma interferon-γ and elevated interleukin-10 levels. The role of CTLA-4was conﬁrmed using CTLA-4 blocking
antibodies, which strongly increased vascular lesion size by 66.7% (p=0.008), compared to isotype-treated
controls.
Conclusions: T-cell CD28–CD80/86 co-stimulation is vital for post-interventional accelerated atherosclerosis
development and is regulated by CTLA-4 co-inhibition, indicating promising clinical potential for prevention
of post-interventional remodeling by abatacept.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Atherosclerosis is a chronic inﬂammatory disease in which endo-
thelial dysfunction leads to retention of oxidized low-density lipopro-
tein (oxLDL) cholesterol particles, attracting leukocytes and leading to
a local inﬂammatory response [1–3]. T-cell subsets have been shown
to play a vital role in this process [4,5]. Unlike native atherosclerosis,
their contribution to post-interventional remodeling and accelerated
atherosclerosis development remains uninvestigated. Although local
intimal hyperplasia consist predominately of smooth muscle cellsMC, Einthoven Laboratory for
PO Box 9600, 2300 RC, Leiden,
66750.
Ltd. All rights reserved.(SMCs) and connective tissue [6], platelet and leukocyte (e.g. T-cells)
adherence and activation have been shown to be driving factors
behind this overshooting inﬂammatory healing response, leading to
re-occlusion [7].
T-cell responses to immunogenic (neo) antigens such as oxLDL
cholesterol are regulated by antigen recognition signals provided by
peptide-MHC antigen complexes on antigen-presenting cells (APCs)
that bind to the T-cell antigen receptor (TCR), which operates in
concert with co-stimulatory signals. The dominant co-stimulatory re-
ceptor CD28 is constitutively expressed on resting T-cells, whereas
Cytotoxic T-Lymphocyte Antigen (CTLA)-4 is a co-inhibitory receptor
expressed on activated T-cells [8,9]. Their ligands CD80 and CD86
are upregulated upon activation and predominantly expressed on
dendritic cells, B cells, andmonocytes/macrophages. CTLA-4 is homolo-
gous to CD28 and binds CD80–CD86 with much higher afﬁnity than
CD28 [10]. During an ongoing immune response, CTLA-4 is upregulated
1966 M.M. Ewing et al. / International Journal of Cardiology 168 (2013) 1965–1974and outcompetes CD28 leading to inhibition of T-cell proliferation and
reduction of interleukin (IL)-2 production [11]. The importance of the
CD28/CTLA-4 pathways has become evident by generating mice ge-
netically deﬁcient in CTLA-4, which develop fatal lymphoproliferative
disease with progressive T-cell accumulation in peripheral lymphoid
and solid organs [12,13].
Upon stimulation, CD4+ T helper 1 (Th1) effector cells upregu-
late CD40 ligand and produce interferon (IFN)-γ, responsible for
pro-atherogenic cellular chemotaxis and macrophage activation [3],
leading to inﬂammation. Blocking of CD28–CD80/86 mediated co-
stimulation by CTLA-4 domain-containing Ig fusion proteins (abatacept),Vehicle CD4-/-A
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Fig. 1. Reduced vascular remodeling in CD4−/− and CD80−/−CD86−/− and abatacept-trea
CD86−/− and abatacept-treated mice (A) after 21 days (hematoxylin–phloxine–saffron (HP
tiﬁcation of intimal thickening (μm2) (B), intima/media ratio (C) and luminal stenosis (%) (D
and abatacept-treated mice (E) after 21 days (α-SMC actin and Sirius Red collagen staining,
SMC (H) and collagen (I) areas (%). Horizontal bars indicate median values, n=10. *pb0.0capable of binding CD80/86 with high-afﬁnity can downregulate T-cell
proliferation [14] and production of tumor necrosis factor (TNF)-α,
IL-2 and IFN-γ in vitro [15]. Abatacept displays little immunogenicity,
with b3% of patients developing an antibody response toward
abatacept [16] and is used to treat rheumatoid arthritis (RA) pa-
tients [17–19]. Although the T-cell [20,21] and CD28–CD80/CD86
co-stimulation [5,22] roles have been demonstrated in native ath-
erosclerosis, their contribution to post-interventional remodeling
and accelerated atherosclerosis development is unknown, as is the
role of CTLA-4.We hypothesized that the CD28–CD80/86 pathway is in-
strumental in post-interventional T-cell-regulated arterial inﬂammationAbataceptCD80-/-CD86-/-
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Fig. 1 (continued).
1967M.M. Ewing et al. / International Journal of Cardiology 168 (2013) 1965–1974and that the co-inhibitory CTLA-4 pathway downregulates these T-cell
responses limiting inﬂammatory-induced intimal thickening.
In the present study, we studied the role of CD4 T-cells and
co-stimulatory cellular activation in post-interventional remodeling
in both CD4−/− and CD80−/−CD86−/− mice using a well-established
mouse model [7,23]. CTLA-4 contribution to this process is investigated
by treating operated C57Bl/6 mice with abatacept. Next, CTLA-4
co-inhibition effects are investigated by studying post-interventional
accelerated atherosclerosis development in hypercholesterolemic
ApoE3*Leiden mice after both abatacept treatment and systemic
CTLA-4 antibody blockade. Our results demonstrate that CD4 T-cells
promote post-interventional atherosclerosis in a CD28–CD80/CD86-
dependent fashion and that CD4 T-cell CTLA-4 co-inhibition regulates
accelerated atherosclerosis development and bears high potential for
prevention of post-revascularization vascular remodeling.
2. Methods
The authors of this manuscript have certiﬁed that they comply with the Principles
of Ethical Publishing in the International Journal of Cardiology.
2.1. Femoral arterial cuff mouse model
All experiments were approved by the Institutional Committee for AnimalWelfare of
the Leiden University Medical Center and the investigations are in conformation with the
Guide for the Care and Use of Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85-23, revised 1996). We performed multiple in vivo
studies in which wildtype (C57Bl/6) control, CD4−/− and CD80−/−CD86−/− mice were
subjected to femoral artery cuff placement to induce vascular injury and remodeling
[7,23]. Both during surgery and sacriﬁce, mice were anesthetized with a combination of
IP injectedMidazolam (5 mg/kg, Roche), Medetomidine (0.5 mg/kg, Orion) and Fentanyl
(0.05 mg/kg, Janssen). This surgery produces concentric intimal lesions that affect vessel
patency and consist predominately of SMCs and connective tissue and is strongly
inﬂammation-dependent [6].
2.2. Abatacept treatment
Treatment with 10 mg/kg abatacept at the time of surgery through intraperitoneal
injection, similarly to that used in clinical treatment of RA and in earlier murine studieswas given to evaluate the role of the CD28–CD80/CD86 co-stimulatory pathway in this
process.
2.3. Vascular wall lesion analysis
In these vascular segments, inﬂammatory cell adhesion, inﬁltration, intimal
thickening and lesion composition were assessed using histology, morphometry
and immunohistochemistry (IHC), as described previously [23]. Samples were stained
with hematoxylin–phloxine–saffron and speciﬁc vessel wall composition was visualized
for elastin, collagen and with antibodies against leukocytes, macrophages, vascular
SMCs, CD3 and CD4 T-cells, matrix metalloproteinase-9 and CTLA-4. This analysis was
repeated in operated hypercholesterolemic ApoE3*Leiden mice to assess accelerated
atherosclerotic lesion phenotype.
2.4. Flow cytometry
Leukocyte subsets were characterized using ﬂow cytometry in spleen and draining
inguinal lymph nodes [24]. These were harvested and single-cell suspensions were
prepared by mincing the tissue through a 70-μm cell strainer. For cell surface staining,
cells were resuspended in staining buffer and incubated with ﬂuorescent conjugated
antibodies. After washing and resuspension in staining buffer, cells were acquired
using a BD LSRII ﬂow cytometer and data was analyzed using FlowJo software. Cells
were stained with ﬂuorochrome-conjugated monoclonal antibodies speciﬁc for CD3,
CD4, CD44, CD25, CD62L CD69, CD127, CTLA-4, and KLRG1 and staining for intracel-
lular FoxP3 was performed using the FoxP3 staining set. 7-AAD was used to exclude
dead cells.
2.5. Biochemical analysis
Plasma IFN-γ and IL-10 levels were determined using ELISA were performed
according to the manufacturer's instructions and total plasma cholesterol was mea-
sured enzymatically.
2.7. Functional CTLA-blockade
CTLA-4 co-inhibition effects on accelerated atherosclerosis development were con-
ﬁrmed using anti-CTLA-4 blocking antibodies [11]. Anti-murine CTLA-4 IgG antibodies
used in this study were isolated from supernatants from the 9H10 hybridoma line.
Antibody concentration was performed using an artiﬁcial kidney and the concentrated
antibodies were protein G-puriﬁed. CTLA-4 blockade in ApoE3*Leiden mice was induced
by injecting animals IP with 200 μg of anti-mouse CTLA-4 or control IgG once every
2 days, starting at the time of surgery.
All materials and methods are described in detail in the supplemental material.
1968 M.M. Ewing et al. / International Journal of Cardiology 168 (2013) 1965–19743. Results
3.1. CD4 T-cells and CD80/86 mediated-co-stimulation are critically
involved in post-interventional vascular remodeling
To investigate the contribution of CD4 T-cells and the CD28/
CTLA-4-CD80/86 pathways to vascular remodeling, we placed femo-
ral artery cuffs in control, CD4−/− and CD80−/−CD86−/− mice and
animals receiving abatacept-treatment. Murine body weights were
similar at surgery and sacriﬁce (Table 1). 21 days after surgery lesions
were stained with hematoxylin–phloxine–saffron (HPS) to visualize
overall vascular wall morphology (Fig. 1A), and revealed that
untreated animals, compared to CD4−/−, CD80−/−CD86−/− and
abatacept-treated mice, developed concentric intimal thickening
leading to luminal stenosis. Weigert's elastin staining was performed
to allow morphometric analysis using the elastic laminae to assess
vessel layer surface area and remodeling. Analysis showed that inti-
mal thickening was reduced by 72.1% (p=0.006) in CD4−/− mice, by
64.2% (p=0.015) in CD80−/−CD86−/−mice and by 58.5% (p=0.029)
in abatacept-treated animals compared to controls (Fig. 1B).Vehicle Abatacept
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Fig. 2. Abatacept prevents accelerated atherosclerosis in hypercholesterolemic mice. Represe
mice following vehicle or abatacept-treatment (A) after 14 days (HPS and Weigert's elast
intimal thickening (μm2) (B), medial area (μm2) (C), intima/media ratio (D) and luminal stSince the total surface area (μm2) of the media was similar in all
groups (Fig. 1B), absence of CD4 T-cells and CD80/86 co-stimulatory
molecules and abatacept-treatment led to reduced intima/media
ratio with respectively 70.0% (p=0.011), 66.4% (p=0.005) and
55.3% (p=0.047, Fig. 1C). Additionally, the percentage luminal stenosis
was reduced in these groups by 48.7% (p=0.042), 47.7% (p=0.031)
and 49.9% (p=0.036) respectively (Fig. 1D). These results indicate a
reduced inﬂammatory-driven remodeling process the injured arterial
segments. The total vessel and luminal areas (μm2) were not different
between all groups (Fig. 1A, C). These data indicate an important role
of CD4 T-cells and the CD28/CTLA-4-CD80/CD86 co-stimulatory axis
in post-interventional vascular remodeling.
3.2. CD4−/−, CD80−/−CD86−/− and abatacept-treated mice display an
altered lesion composition during post-interventional vascular remodeling
Lesion composition was analyzed using IHC, which showed larger
relative areas (to the total vessel layer surface area) of α-SMC actin
in the media by 15.8% (p=0.028) in CD4−/− and 16.1% (p=0.028)
in abatacept-treated mice (Fig. 1E), while α-SMC actin+relativeVehicle Abatacept
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ntative cross-sections of cuffed-femoral arteries of hypercholesterolemic ApoE3*Leiden
in staining, 80×, arrows in inserts indicate internal elastic laminae). Quantiﬁcation of
enosis (%) (E). Horizontal bars indicate median values, n=10. *pb0.05.
1969M.M. Ewing et al. / International Journal of Cardiology 168 (2013) 1965–1974area in the intima was signiﬁcantly decreased compared to controls
by 31.6% (p=0.001) and 29.3% (p=0.019) respectively (Fig. 1G).
Both medial (Fig. 1H) and intimal (Fig. 1I) relative collagen areas (%)
were similar between groups, reﬂecting absolute α-SMC actin+and
collagen areas (μm2) in the media (Fig. IIA, C). Total α-actin+SMC
area (μm2) in the intima was only reduced in CD4−/− mice by 59.7%
(p=0.008) while collagen area (μm2) remained unchanged (Fig. IIB,
D) with limited CD45 leukocyte and CD4 T-cell inﬁltration in the
vascular layers in control sections (Fig. IIE), indicating an indirect
but clear effect of CD4 T-cells upon vascular SMC proliferation and
migration.A
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Fig. 3. Abatacept positively affects accelerated atherosclerotic lesion composition. Represen
or abatacept-treatment (A) after 14 days (leukocyte, macrophage and α-SMC actin stainin
areas (%) and intimal leukocyte (C), macrophage (E) and SMC (G) areas (%) and intimal C
(K). Horizontal bars indicate median values, n=10. *pb0.05, **pb0.01. (L) T-cell CTLA-4
and 3 days and 14 days after surgery (CTLA-4 and CD4 staining, 80×, arrows in inserts ind3.3. Abatacept prevents accelerated atherosclerosis
The contribution of the CD28–CD80/CD86 co-stimulatory pathway
to accelerated atherosclerosis development was tested in a preclinical
model of accelerated atherosclerosis development in Western-type
diet-fed hypercholesterolemic ApoE3*Leiden mice using abatacept
as therapeutic intervention strategy. Plasma cholesterol concentra-
tions (12.1±3.1 mmol/L) were similar in all groups throughout this
study (Table 2). Vehicle and abatacept-treated ApoE3*Leiden mice
were sacriﬁced 14 days after arterial cuff placement and accelerated
atherosclerotic lesions were stained with HPS to visualize overallphages
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1970 M.M. Ewing et al. / International Journal of Cardiology 168 (2013) 1965–1974vascular morphology (Fig. 2A). This revealed that vehicle-treated
animals developed concentric intimal thickening and luminal ste-
nosis, consisting of connective tissue with profound cellular inﬁl-
tration which was absent in abatacept-treated mice. Quantitative
analysis of cuffed arteries stained with Weigert's elastin identiﬁed
reduced intimal thickening after abatacept treatment with 78.1%
(p=0.040, Fig. 2B). Abatacept also decreased absolute medial sur-
face area (μm2) by 22.9% (p=0.040, Fig. 2C), and intima/media
ratio by 69.5% (p=0.037, Fig. 2D). Furthermore, luminal stenosis
percentage was reduced by 48.2% (p=0.021, Fig. 2E), identifying
a potent role for CTLA-4 co-inhibition controlling inﬂammatory
post-interventional vascular remodeling. The total vessel and luminal
areas (μm2) were similar in the abatacept-treated group, although
a trend toward reduced total vessel area by 34.6% was observed
(p=0.094) (Fig. IIIA, B).
3.4. Abatacept positively affects accelerated atherosclerotic lesion
composition
Lesion composition was analyzed using IHC to allow arterial wall
inﬂammatory phenotype assessment (Fig. 3A). Abatacept-treatment
produced an altered lesion composition with a reduced inﬂamma-
tory phenotype. Abatacept reduced leukocyte and macrophage/foam
cell fractions (% of all cells) in the media by 64.0% (p=0.043,
Fig. 3B) and 72.1% respectively (p=0.003, Fig. 3D) and intima by
73.9% (p=0.009, Fig. 3C) and 30.5% (p=0.048, Fig. 3E), respectively.
Abatacept-treatment also led to a comparable medial (p=0.602,
Fig. 3F) and 29.8% (p=0.042, Fig. 3G) increased intimal α-SMC actin
surface area (%), although absolute intimal SMC area (μm2) was not in-
creased (p=0.743, Fig. IVA), similarly to the tunica media (p=0.888,
Fig. IVB). Whereas limited CD3 T-cells and matrix metalloproteinase-9
expressing cells could be detected in the tunica intima (Fig. 3H, I),
corresponding with a similar collagen quantity in the intima, abatacept
reduced these cells in the tunica adventitia by 65.9% (pb0.0001, Fig. 3J)
and 64.7% (pb0.0001, Fig. 3) respectively.T-cell CTLA-4 and CD4 co-localized expressionwas identiﬁed using
IHC in the injured arterial segments of vehicle-treated ApoE3*Leiden
mice and was absent in uninjured arteries, but occurred 3 days after
surgery and could still be observed 14 days after injury, indicating
continuing local arterial T-cell activation throughout the remodeling
process and accelerated atherosclerosis development (Fig. 3L).
3.5. Abatacept prevents systemic CD4 T-cell activation during accelerated
atherosclerosis
To examine the role of CTLA-4 co-inhibition upon T-cell activation
involved in accelerated atherosclerosis development, CD4 T-cell num-
bers and T-cell activation status were assessed. The markers Killer
cell lectin-like receptor subfamily G member (KLRG)-1, Programmed
Death (PD)-1, CD69 and CTLA-4 were used to analyze T-cell activa-
tion in the splenic reservoir and draining inguinal lymph nodes of
mice 14 days after surgery.
Absolute CD4 (p=0.557, Fig. 4A) splenic T-cell numbers were
similar in vehicle and abatacept-treated mice, as were total splenic
cell contents (absolute cells) and percentages CD4 T-cell fractions
(Fig. VA, B). Abatacept reduced splenic CD4 T-cells fractions expressing
CD69 by 61.9% (p=0.008, Fig. 4B), PD1 by 49.4% (p=0.041, Fig. 4C),
KLRG1 by 47.4% (p=0.032, Fig. 4E), and CTLA-4 by 47.0% (p=0.016,
Fig. 4F). These data indicate that abatacept strongly and consis-
tently prevented systemic CD4 T-cell activation, thereby reducing
accelerated atherosclerotic lesion formation. In contrast to the re-
duced severity of inﬂammatory vascular remodeling, co-inhibition
with abatacept treatment also reduced fractions of CD4+CD25+
FoxP3+ regulatory T-cells by 33.3% (p=0.016, Fig. 4H) in the
spleen. No signiﬁcant differences in the percentages of naive
(CD62L+CD44−), central-memory (CD62L+CD44+) or effector-
memory (CD62L−CD44+) CD4 T-cell populations were observed
(p>0.05, Fig. VC–F).
Contrary to signiﬁcant reduction of activated CD4 T-cells in the
spleen after abatacept-treatment, no evidence of T-cell activation in
CD44
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Fig. 4. Abatacept prevents systemic CD4 T-cell activation in ApoE3*Leiden mice. Abatacept did not affect total CD4 splenic T-cell count (absolute cells) 14 days after surgery
(A). T-cells were analyzed using multiparametric ﬂow cytometry and gated for 7AAD−, CD3+ and CD4+ markers and subsequently for either KLRG1+, PD1+, CD69+,
CTLA-4+ or CD25+ and FoxP3+ expression and are displayed in dot plots (D and G). Abatacept reduced CD69+ (B), PD1+ (C), KLRG1+ (E) and CTLA-4+ (F) activated CD4
T-cell fractions (%), together with CD25+FoxP3+ regulatory (H) CD4 T-cell fractions (%). Horizontal bars indicate median values, n=5. *pb0.05, **pb0.01.
1971M.M. Ewing et al. / International Journal of Cardiology 168 (2013) 1965–1974draining inguinal lymph nodes could be found (Fig. VIA–G), despite
adequate cell number isolation for analysis.
3.6. Abatacept affects systemic cytokine levels during accelerated
atherosclerosis
Contribution of activated T-cell fractions to vascular remodeling
severity is supported by the positive correlation (R2=0.61, p=0.002)
between KLRG1+ CD4+ T-cells (%) and intimal thickening (μm2)
(Fig. 5A). Interestingly, the ratio between regulatory and effector helper
T-cells remained unchanged in treated animals (Fig. 5B). Affected sys-
temic CD4 T-cell activation in abatacept-treated mice was investigated
by IFN-γ and IL-10 measurements in plasma at 14 days. Hypercholes-
terolemic control animals contained an elevated plasma concentrationIFN-γ of 43.2±12.1 pg/ml, while abatacept-treatment reduced the
IFN-γ concentration to non-detectable levels (p=0.00023, Fig. 5C)
after vascular injury. In contrast, plasma IL-10was signiﬁcantly elevated
from 4.5±2.0 pg/ml in controls to 23.7±7.1 pg/ml (p=0.012, Fig. 5D)
in abatacept-treated mice. Together, these cytokines indicate that
abatacept reduced systemic inﬂammation.
3.7. CTLA-4 blockade exacerbates accelerated atherosclerosis development
To conﬁrm the anti-inﬂammatory role of CTLA-4 co-inhibition
in accelerated atherosclerotic lesion development, we analyzed in-
jured femoral lesions of mice undergoing CTLA-4 blockade using
antibodies. HPS staining (Fig. 6A) revealed that CTLA-4 blocking
provoked increased accelerated atherosclerosis development and
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1972 M.M. Ewing et al. / International Journal of Cardiology 168 (2013) 1965–1974decreased luminal patency. Weigert's elastin staining and morpho-
metric vessel wall analysis conﬁrmed increased intimal thickening
by 66.7% compared to control mice receiving non-speciﬁc anti-β gal
IgG (p=0.008, Fig. 6B). Due to a comparable medial area between
groups, the intima/media ratio was increased by 69.3% (p=0.010,
Fig. 6C). Finally, CTLA-4 blockade increased relative luminal stenosis
by 86.3% (p=0.004, Fig. 6D) and compromised absolute luminal area
by 56.9% (p=0.010, Fig. 6E). Total vessel and medial areas (μm2)
were both not different between groups (Fig. VIIA, B). Together,
these results indicate a strong increase of inﬂammatory induced post-
interventional vascular remodeling during functional blockade of
CTLA-4 function.
3.8. Accelerated atherosclerotic lesion phenotype is preserved during
CTLA-4 blockade
Lesion composition was analyzed using IHC to assess arterial wall
inﬂammatory phenotype (Fig. VIIIA). Although CTLA-4 blockade en-
hanced accelerated atherosclerosis development, no lesion composi-
tion differences were observed compared to controls. There were
similar leukocyte and macrophage/foam cell fractions (% of all cells)
in the media (p=0.414, Fig. VIIIB; p=0.097, Fig. VIIID, respectively)
and intima (p=0.142, Fig. VIIIC; p=0.769, Fig. VIIIE, respectively).
CTLA-4 blockade also led to a comparable medial (p=0.728, Fig. VIIIF)
and intimal (p=0.258, Fig. VIIIG) α-SMC actin surface areas (%). IHC
revealed that functional CTLA-4 blockade led to a signiﬁcant increase
of CD3+ T-cells (n) in both the tunica intima by 200.0% (p=0.0001,
Fig. 6F) and in the tunica adventitia by 241.4% (p=0.0003, Fig. 6G)
compared to controls.
4. Discussion
This study demonstrates an important role for T-cell co-stimulation
by CD28–CD80/CD86 and the negative regulator CTLA-4 in post-
interventional intimal hyperplasia and accelerated atherosclerosis
development. We show that CD4−/− and CD80−/−CD86−/− mice
develop signiﬁcantly smaller SMC-rich lesions following vascular in-
jury and that inﬁltrated T-cells express CTLA-4 early after surgery.Therapeutic inhibition of CD28–CD80/86 function by abatacept signiﬁ-
cantly prevented accelerated atherosclerosis development in hypercho-
lesterolemic ApoE3*Leiden mice together with reduced IFN-γ plasma
concentration (Fig. 5C), probably due to reduced CD4 T-cell activation.
The role of CTLA-4 co-inhibition was conﬁrmed using blocking anti-
bodies which led to profound increased vascular lesion size.
The role of CD4 T-cells and CD80/86-mediated co-stimulation during
native atherosclerosis development [25,26] has been investigated, but
their contribution to post-interventional vascular remodeling remained
until this study unknown. In ApoE−/− mice, T-cells have been shown
to be important in early native atherosclerotic lesion progression, but
not its initiation [26,27]. We provide evidence for activated CD4 T-cell
involvement in the early stage of vascular remodeling following inter-
vention. As of yet, it remains to be investigated toward which antigen
the T-cell response is raised. Nevertheless, this form of accelerated
atherosclerosis develops withinmonths and in a localized area, opening
the perspective for (local) T-cell-directed treatment directly after per-
cutaneous coronary interventions.
CTLA-4 is expressed on activated effector T-cells and constitu-
tively on regulatory T-cells, while both CD80 and CD86 are primarily
expressed on activated dendritic cells, B cells, monocytes/macrophages,
which play an important role in native atherosclerosis development [4].
T-cell-mediated immune responses are initiated in lymphoid tissues
where they are activated by APCs presenting two concomitant signals:
an antigenic signal provoked by speciﬁc MHC-antigen peptide com-
plexes that bind to the TCR and a co-stimulatory signal induced by
CD80 and CD86 molecules that interact with CD28 expressed on all
T-cells. Together, TCR and CD28 signals lead to an inﬂammatory and
pro-atherogenic response. We show that abatacept-treatment was
able to prevent this systemic activation by reducing the number of acti-
vated CD4 T-cells fractions in the spleen as evidenced by the activation
markers KLRG1, PD1, CD69 and CTLA-4. Since vascular injury occurs
locally, profound T-cell activation was expected to occur in draining
lymph nodes. However, only low fractions of activated T-cells were
identiﬁed in these lymph nodes (Fig. 6A–G) while analysis of splenic
T-cell fractions revealed signiﬁcant activation (Fig. 4A–F). We cannot
exclude effects of abatacept in other lymphnodes, but these are unlikely
to supersede the effects in the analyzed primary draining lymph nodes.
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1973M.M. Ewing et al. / International Journal of Cardiology 168 (2013) 1965–1974Although abatacept effects on accelerated atherosclerosis are
mediated through systemically reduced T-cell activation, it is not
clear to which extent effects on speciﬁc T-cell subsets contributed to
the lesion development. Buono et al. [22] showed that CD80−/−
CD86−/−LDL-receptor (r)−/− mice developed decreased atheroscle-
rotic lesions compared to LDL-r−/− mice through reduced CD4 Th1
cell activation by CD80/86 on APCs. Unlike activated effector T-cells,
regulatory CD25+ FoxP3+ T-cells constitutively express CTLA-4
[28] and this is essential for their suppressive function [29,30].
Ait-Oufella et al. [5] demonstrated the vital role of regulatory T-cells
in native atherosclerosis development , using irradiated LDL-r−/−
mice receiving reconstituted bone-marrow from CD80−/−CD86−/−
mice which developed increased atherosclerotic lesions through
strongly reduced splenic fractions of regulatory CD25+FoxP3+
T-cells. Therefore, it is possible that abatacept, may have inhibitory ef-
fects on accelerated atherosclerosis development through regulatory
T-cell activation status modulation. However, Platt et al. showed
that abatacept prevented effector T-cell activation, although effectson regulatory T-cell status in this murine arthritis model were not
studied [14].
This study shows reduced fractions of both activated Th1 and regu-
latory T-cells in hypercholesterolemic ApoE3*Leiden mice receiving
abatacept. Since the Th1: regulatory T-cell ratio remained unchanged
(Fig. 5B), this strongly suggests that therapeutic effects of abatacept
can primarily be attributed to directly reduced activation of Th1
T-cells and not to Th1 suppression through regulatory T-cells, reﬂected
by an elevated concentration of IL-10 (Fig. 5D) in plasma (baseline
14.4±2.3 pg/ml) [23] and reduced concentration of IFN-γ (Fig. 5C)
(baseline 9.8±4.6 pg/ml) [23], similarly to that observed following
IL-12 vaccination by Hauer et al. which downregulated the Th1 im-
mune response and led to attenuation of native atherosclerosis de-
velopment [31].
These ﬁndings are based upon results from animal studies and can-
not be automatically extrapolated to the clinical situation. However,
they do provide further insight into the role of T-cell co-stimulatory
pathways when viewed in the light of recent exiting data by Dumitriu
1974 M.M. Ewing et al. / International Journal of Cardiology 168 (2013) 1965–1974et al. [32] concerning the role of CD28−/− activated T-cells and regu-
latory T-cells during acute coronary syndromes (ACS) in humans, as
well as carotid stenosis [33], unstable angina [34,35] and atherosclero-
sis development in both humans [36] and animals in general [37]. The
function relevance of CTLA-4 expression for human peripheral T-cell
has previously been shown by Hoff et al. [38] and Yi-qun et al. [39],
in which CTLA-4 blockade was found to both determine CD28null
T-cell and memory T-cell longevity and responsiveness (e.g. IL-2
production). The potential of co-stimulatory-based T-cell-directed
intervention strategies in the clinical situation is further enhanced
by the ﬁndings of Bluestone et al. [40] and Körmendy et al. [41], in
which functional CTLA-4 blockade functionally affected circulating
regulatory T-cells in patients undergoing kidney transplantation and
peripheral Th cells in rheumatoid arthritis patients. This study demon-
strated the effectiveness of modulation of co-stimulatory receptors
against post-interventional atherosclerotic vascular remodeling in
mice, thus greatly enhancing the potential of a similar therapeutic
approach to improve the survival of ACS patients.
In conclusion, this study shows that T-cell co-stimulation through
the CD28–CD80/86 pathway plays a vital role in post-interventional
accelerated atherosclerosis development and is strongly negatively
regulated by CTLA-4 co-inhibition. These results may have important
clinical implications. Immune-mediated interventions directed toward
therapeutically controlling the inﬂammatory T-cell response such as
abatacept are widely applied in other immune (e.g. rheumatoid) disor-
ders and could now be used in an early phase following interventions
such as revascularization or bypass grafting procedures in patients
to prevent subsequent vascular remodeling. This application could be
accelerated by the availability of abatacept as a currently clinically
approved T-cell speciﬁc therapeutic agent.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ijcard.2012.12.085.
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